SuperworthCentene Corp. CNC
Medical - Healthcare Plans, Healthcare
$64.99
+0.59%
- Market cap
- $32.1B
- PE
- —
- 10y median 20.7×
- Forward PE
- Price to sales
- 0.2×
- EV/EBIT
- 19.8×
- Revenue, 12 months
- $202.9B
- +14% on a year ago
- Net margin
- −2.5%
- Free cash flow yield
- 27.9%
Centene trades at 0.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $202.9B over the last twelve months, up 14% on a year earlier with a −3% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $39.5B | $40.4B | $39.8B | $42B | $40.8B+3% | $46.6B+15% | $48.7B+22% | $49.7B+18% | $49.7B+22% | $49.9B+7% | $53.6B+10% | |
| Cost of revenue | $30.6B | $30.9B | $30.8B | $32.2B | $31.8B+4% | $36.5B+18% | $38.8B+26% | $40.9B+27% | $41.5B+30% | $39B+7% | $39.8B+2% |
| Gross profit | $3.7B | $4.6B | $4.4B | $4B | $3.7B+2% | $5.2B+12% | $2.9B−34% | $8.1B+102% | $7.5B+103% | $10.9B+110% | $4.6B+57% |
| SG&A | $3.5B | $3.2B | $2.9B | $3.1B | $3.2B−7% | $3.4B+4% | $3B+5% | $3.1B+3% | $3.4B+4% | $3.4B+1% | $3.1B+2% |
| −$194M | $1.1B | $1.2B | $665M | $175M | $1.5B+39% | −$458M | −$7B | −$1.7B | $1.9B+21% | $1.2B | |
| Interest expense | $183M | $178M | $176M | $176M | $172M−6% | $170M−5% | $170M−3% | $170M−3% | $168M−2% | $164M−4% | $153M−10% |
| Pre-tax income | $24M | $1.5B | $1.5B | $921M | $347M+1346% | $1.7B+19% | −$257M | −$6.7B | −$1.5B | $2.1B+20% | $1.5B |
| −$15M | $315M | $370M | $211M | $67M | $432M+37% | $2M−100% | −$42M | −$443M | $560M+30% | $399M+19850% | |
| Net income | $45M | $1.2B | $1.1B | $713M | $283M+529% | $1.3B+13% | −$253M | −$6.6B | −$1.1B | $1.5B+18% | $1.1B |
| $0.08 | $2.16 | $2.16 | $1.36 | $0.56+569% | $2.63+22% | −$0.51 | −$13.50 | −$2.24 | $3.11+18% | $2.19 | |
| 537.6M | 538.1M | 530.8M | 523.5M | 502M−7% | 498.2M−7% | 493.5M−7% | 491.1M−6% | 491.1M−2% | 495.6M−1% | 497.6M+1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Healthcare Plans within ten times Centene's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CNCCentene Corp. | $32.1B | — | 20.7× | 0.2× | +14% | −2.5% | |
| HUMHumana Inc. | $47.6B | 37.5× | 20.5× | 0.3× | +18% | 0.9% | |
| CICigna Corporation | $73.6B | 11.5× | 16.1× | 0.3× | +8% | 2.3% | |
| ELVElevance Health Inc. | $87.7B | 18.0× | 17.6× | 0.4× | +6% | 2.5% | |
| CVSCVS Health Corp. | $112.5B | 23.3× | 16.2× | 0.3× | +7% | 1.2% | |
| Peer median | $80.6B | 20.6× | 16.9× | 0.3× | +8% | 1.7% |
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .